Fortunately, novel anti-diabetic agents, including sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA), have demonstrated significant cardiovascular benefits.6–8 Both SGLT2i and GLP-1 RA have been shown to reduce major adverse cardiovascular events (MACE) in patients with ASCVD, while SGLT2i has also been proven to improve outcomes in patients with HF.9 This evidence concerns the gene GLP1R and atherosclerosis.